Paris Brain Institute to study neurological impact of COVID-19, supported by FIA Foundation

Main Image
The ICM, a world renowned research institute, was established in 2006 with multi-million euro support from the FIA Foundation.
The ICM, a world renowned research institute, was established in 2006 with multi-million euro support from the FIA Foundation.
Lead researcher of the ICM C19 project, Prof Jean-Yves Delattre, is the Medical Director of the Paris Brain Institute and Director of the AP-HP-Sorbonne University Neuroscience Medico-University Department at the Pitié-Salpêtrière Hospital.
Lead researcher of the ICM C19 project, Prof Jean-Yves Delattre, is the Medical Director of the Paris Brain Institute and Director of the AP-HP-Sorbonne University Neuroscience Medico-University Department at the Pitié-Salpêtrière Hospital.

The neurological and psychiatric impacts of COVID-19 are the focus of a major new study by the Paris Brain Institute (ICM), supported by a €400,000 grant from the FIA Foundation, to better understand the long-term impact and potential rehabilitation treatments for those affected by the disease.

The study will be undertaken in partnership with the Medico-University Department of Neurosciences at the Pitié-Salpêtrière Hospital, with the support of the FIA Foundation which is a long-term patron of the Institute, and from the FIA.

Beyond the respiratory issues predominantly associated with COVID-19, many other organs can be affected and lead to neurological complications such as loss of smell, loss of taste, headaches, dizziness, convulsions, stroke, altered consciousness, and muscular issues (hemiplegia). In addition, respiratory difficulties observed in patients with Covid-19 may also linked to brain stem involvement in breathing control. So far, experts know little about the overall impact on the central nervous system, nor the psychological impacts, despite the fact that more than 9 million people worldwide are currently affected by the virus.

The study will focus on: the neuropsychiatric manifestations of the affected individuals; the psychiatric consequences for the patients themselves (due in particular to very long periods of resuscitation) as well as for their relatives; the consequences for patients already suffering from neurological pathologies such as inflammatory diseases (including multiple sclerosis) and neurodegenerative diseases (such as Parkinson's and Alzheimer's). The data collected will be the subject of in-depth analysis using artificial intelligence to provide insights and potential treatment options.

Gérard Saillant, President of the Paris Brain Institute and President of the FIA Medical Commission said: "At the Paris Brain Institute, our mission is to find in order to cure. Therefore, the observations of our eminent specialists on this study will be decisive in helping people with Covid-19 to receive appropriate care. This ambitious project is led by the Neuroscience Medico-University Department at the Pitié-Salpêtrière hospital and the clinicians-researchers at the Paris Brain Institute, thanks to the FIA and the FIA Foundation, in favour of health for all. I would like to thank them very warmly."

"The long-term effects of the coronavirus on health are only beginning to be understood, so this important project will provide vital information to share with the world. We at the FIA Foundation are proud of our longstanding relationship with the Institute and its cutting-edge research," commented Saul Billingsley, Executive Director of the FIA Foundation.

In a research team statement, Prof. Jean-Yves Delattre, Medical Director of the Paris Brain Institute and Director of the AP-HP-Sorbonne University Neuroscience Medico-University Department at the Pitié-Salpêtrière Hospital, Prof. Jean-Christophe Corvol, Scientific Director of the project, and Dr. Delorme, Principal Investigator, added: "The Paris Brain Institute is probably one of the few centres in the world that is able to provide a comprehensive view of the neurology and psychiatry of Covid-19 infection. In the medium term, this will enable us as health professionals to be prepared to face a new pandemic and to have all the weapons at our disposal to better fight it. We can also think that this infection, when it strikes brains already damaged by a neurodegenerative or inflammatory disease, could have unknown effects. It is very important to know whether we are going to observe very atypical developments, for example in patients being monitored for Alzheimer's disease or multiple sclerosis. There's still a lot we don't know."